L. Velez

P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC): Topic: IT Biomarkers

E. Felip, A. Navarro, S. Martinez, 2017 .

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

E. Van Cutsem, J. Tabernero, R. Yaeger, 2021, ESMO open.

SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

J. Tabernero, R. Yaeger, S. Kopetz, 2020 .